arrow
J

John H. Beigel

national institutes of health
H指数:40
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

与原型加强针mRNA疫苗接种相比,Omicron BA.1基线加强针mRNA疫苗接种对COVAIL试验中COVID-19发病率的影響

Vaccine
IF3.5
2025-09-090
OAAI
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

使用双价信使核糖核酸严重急性呼吸综合征冠状病毒2疫苗加强接种后的黏膜和系统性抗体应答

2025-04-290
PRE
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir

SARS-CoV-2 RNA和核衣壳抗原是与严重疾病结局相关的血液生物标志物,对Remdesivir的反应有所改善

2024-04-243
OA
Clinical and molecular characterization of children and adults with respiratory bocavirus infection in Mexico: a cross- sectional nested study within the ILI002 prospective observational study
2024-01-011
OAAI
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
2023-08-2819
OAAI
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
2023-08-101
OA
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
2023-07-1117
OAAI
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
2023-04-196
OAAI
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
2023-04-1011
OA
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
2022-09-0173
OAAI
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
2022-07-01126
OAAI
Different Clinical Presentations of Human Rhinovirus Species Infection in Children and Adults in Mexico
2022-06-175
OAAI
Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2
2022-04-271
OAAI
Homologous and Heterologous Covid-19 Booster Vaccinations
2022-03-17399
OAAI